CDEX to Showcase ID2 Line and ValiMed™ G4 System at the ACA – 2012 Winter Conference
TUCSON, AZ–(Marketwire – Jan 18, 2012) – CDEX Inc. (OTCBB: CEXI), a leading developer of chemical detection products using patented technologies for use in healthcare, safety and security markets, to showcase the ID2 Meth Scanner, Pocket ID2 illicit drug detector and the ValiMed™ G4 (VG4) multi-component medication and narcotic detection system at the American Correctional Association (ACA) – 2012 Winter Conference. The ACA conference is being held at the Phoenix Convention Center in Phoenix, Ariz., January 20-25, 2012. The complete CDEX product line will be showcased at booth 902 at the conference.
“The ACA conference is the largest correctional gatherings of its kind in the world, ACA’s conventions provide attendees with an opportunity to personally interact with key members and technology providers in the correctional industry face-to-face,” stated Jeff Brumfield, chairman and chief executive officer of CDEX. “We will be showcasing our three primary products at the conference including our ValiMed G4 which is applicable for use in verifying illicit substances in the police or correctional lab environment as well as the healthcare setting. We believe the VG4 may have many future applications aside from healthcare and security, and the ACA conference is a great opportunity to showcase its versatility.”
The American Correctional Association is the oldest and largest international correctional association in the world. ACA serves all disciplines within the corrections profession and is dedicated to excellence in every aspect of the field. From professional development and certification to standards and accreditation, from networking and consulting to research and publications, and from conferences and exhibits to technology and testing, ACA is the resource and world-wide authority in corrections.
CDEX develops, manufactures and globally distributes products to the healthcare, safety and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and pharmacy returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched. To learn more about CDEX please visit: www.cdex-inc.com.
Safe Harbor Statement
Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.